Tanezumab: A Comprehensive Dive into the 880266-57-9 Reagent Product
Tanezumab: A Comprehensive Dive into the 880266-57-9 Reagent Product
Blog Article
Tanezumab, identified by the chemical designation 880266-57-9, represents a therapeutic antibody solution demonstrating significant application in treating debilitating osteoarthritis pain. This humanized antibody uniquely targets nerve growth factor , inhibiting its activity and thereby diminishing discomfort within affected locations. The experimental data surrounding 880266-57-9 highlights its power to provide noticeable discomfort alleviation while potentially mitigating the requirement for conventional analgesics. Further research are currently underway to thoroughly evaluate its lasting safety and performance.
Comprehending Tanezumab's Function in Ache Control: An Antibody Perspective
Tanezumab, a unique medicinal approach, offers a distinct pathway in persistent pain alleviation. As a humanized antibody, it selectively targets and blocks nerve expansion factor (NGF), a important molecule engaged in nerve ache signaling. Unlike standard opioid medications, tanezumab’s protein mechanism allows for a greater targeted action, potentially lessening the likelihood of some frequent side consequences associated with systemic pain reduction. However, its immunological nature necessitates a careful assessment of potential immune responses and long-term effects when employed within a full pain therapy program.
Tanezumab Solution (880266-57-9): Quality , Grade & Functions
The Tanezumab Compound with the identifier 880266-57-9 is a essential component in various scientific applications, particularly concerning joint pain treatment development. Achieving a high level of quality is paramount; therefore, rigorous analysis protocols are employed to guarantee its suitability for intended use. Our manufacturing process focuses on maximizing purity , employing sophisticated purification techniques to remove contaminants . Typical parameters include a >95% purity level as determined by Liquid Chromatography and comprehensive testing for biochemical integrity. The primary uses revolve around its role as a experimental agent for investigating processes of cartilage damage and developing novel treatment strategies .
- Research Investigations
- Therapeutic Development
- Pathway Studies
The Investigation Of Tanezumab: Analyzing the 880266-57-9 Protein
Tanezumab, identified with the molecular identifier 880266-57-9, represents a innovative therapeutic antibody targeting pain-sensing growth substance receptor (NGF). The process of action revolves about specifically connecting to NGF, consequently blocking its function and following signal propagation. Scientists have revealed that this biological compound presents potential for reducing persistent pain, particularly linked to illnesses like osteoarthritis and peripheral back discomfort. More research are underway to thoroughly characterize its effectiveness and security profile.
Recent Developments in Tanezumab Investigation: Examining the Its Reagent
Future analyses surrounding tanezumab, a novel therapeutic compound, are increasingly centered on defining the role of the identified reagent, 880266-57-9. This identification and precise assessment of the chemical entity suggests vital for improving the drug's efficacy and reducing possible undesirable reactions. Early findings indicate that the reagent contributes a important part in tanezumab’s process of action. Further studies will be required to fully elucidate this reagent's effect.
Tanezumab Antibody (880266-57-9): Production, Characteristics, and Potential
The production process of tanezumab, an humanized monoclonal antibody (identified by CAS number 880266-57-9), typically involves mammalian cell culture, often utilizing Chinese hamster ovary cells for high yield. Its here primary characteristic is its ability to selectively target and degrade cathepsin-K, an enzyme crucial for bone resorption. This binding mechanism results in a significant reduction in osteoclast activity. The molecule exhibits a defined molecular weight and specific amino acid sequence, allowing for detailed characterization through techniques such as mass spectrometry and protein sequencing. Consequently, tanezumab’s potential lies in treating conditions characterized by excessive bone loss, like osteoarthritis and metastatic bone disease, although clinical development has been complex due to adverse event profiles and ongoing evaluation.}
Report this page